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1. Introduction 
Atherosclerotic renovascular disease (ARVD), also known as atherosclerotic renal artery 
stenosis is increasingly recognized to be a cause of chronic renal failure. According to a 
recent administrative data regarding general population of the elderly greater than 65 years 
of age in the United States, the prevalence and incidence rates of ARVD were estimated 
0.5% and 3.7 per each 1000 person-years respectively (Kalra et al., 2005). In addition, some 
epidemiological researches demonstrated that the prevalence among those with end-stage 
renal disease beginning renal replacement therapy was estimated from 5% to 22% (Rimmer 
& Gennari, 1993; Mailloux et al., 1994; Appel et al., 1995; van Ampting et al., 2003). Of note, 
ARVD is not only responsible to impaired kidney function but also reflects a status of 
patients at risk for systemic cardiovascular diseases (Kalra et al., 2005). It has been well 
known that a variety of risk factors for atherosclerosis share common pathway underlying 
atherosclerotic renal artery stenosis, coronary artery disease, and peripheral vascular 
disease. On the contrary, significant high-grade bilateral or isolated renal artery stenosis 
may cause renovascular hypertension estimating over 50% of ARVD populations by 
activation of renin-angiotensin-aldosterone system and lipoxygenase pathway that further 
deteriorate the kidney function (Romero 1997). A previous report uncovered that ARVD 
was estimated from 1% to 6% in patients with hypertension (Simon et al., 1972). In this 
regard, a vicious cycle will be established in the progression of renal arterial atherosclerosis, 
which is characterized by refractory hypertension, acute cardiac events (ie, heart failure, 
cardiogenic pulmonary edema or acute coronary syndrome), and hence leads to acute or 
chronic renal failure due to hypertensive or ischemic nephropathy (Buller et al., 2004). 
Therefore, an early alert of patients at risk for ARVD is critical in slowing down the rate of 
kidney function loss and providing treatment for underlying cardiovascular disease as well. 
In this chapter, we will fuel the readers with the classic knowledge in this field and propose 
the latest evidence-based medicine to manage patients with this disease. 
2. The pathogenesis of atherosclerosis 
Atherosclerosis is affected by the traditional risk factors including hypertension, smoking, 
hyperlipidemia, diabetes mellitus and family history of premature coronary artery disease 
systemically. Regionally, blood flow disturbances near arterial branches, bifurcations and 
curvatures result in complex spatiotemporal shear stresses that are associated with 
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atherosclerosis susceptibility (Davies, 2009). In these predisposed areas, hemodynamic shear 
stress, the frictional force acting on the endothelial cell surface is weaker than in protected 
regions. Studies have identified shear stress to be an important determinant of endothelial 
function and phenotype. High shear stress (>15 dyne/cm2) induces endothelial quiescence 
and an atheroprotective gene expression profile, while low shear stress (<4 dyne/cm2), 
which is prevalent at atherosclerosis-prone sites, stimulates an atherogenic phenotype 
(Malek et al, 1999). As we know, thrombosis formation in situ and distal embolic dislodge 
from great vessels, determined by the burden and the stability of atherosclerosis, are the two 
major mechanisms leading to target organ infarction. With recent substantial evidence, 
systemic inflammation caused by either external stimulus such as microbial infection or 
internal immunologic response may trigger acute vascular events via pathogenic athroma 
plaque rupture. Therefore, when and how to stablize and regress the process of 
atherosclerosis becomes a cirtical step to prevent target organ damage. 
2.1 Systemic arterial atherosclerosis: the evidence from angiography and autopsy 
Advanced atherosclerosis is highly prevalent among patients with ARVD characterized by 
coexistence with abdominal aortic aneurysm, severe coronary artery disease, ischemic stroke 
and peripheral vascular disease in post-mortem and angiographic studies (Table 1). 
 
 
ANG 
(Patient: n) 
Age 
(year) 
CAD  
(%) 
PAD 
(%) 
ARVD   
(%) 
Predictors 
Crowley, 
1998 
CAD: 14,152 61+12 63% NA 
6.3% 
(bil: 1.3%) 
Predictors for ARVD 
progression: 
-Female gender, OR: 1.8 
-PAD, OR: 1.8 
-Hypertension, OR: 1.5 
-significant CAD, OR: 1.2 
Conlon,  
2001 
CAD: 3,987 61+9 100% NA 
9.1% 
(4.8%)* 
-CAD: 2VD vs.1VD, OR: 1.9  
-CAD: 3VD vs 1VD, OR: 2.5 
Liu,  
2004 
CAD: 141 59+10 31% NA 18.4% -CAD vs. non-CAD, HR: 2.8 
Leandri, 
2004 
CAD: 467 64+11 69% NA 9.0% 
-CAD: 2VD vs.1VD, OR: 2.8  
-CAD: 3VD vs 1VD, OR: 3.0 
Buller, 
2004 
ARVD: 837 67+10 68% 
-Carotid: 12% 
-A.A.A or lower limb 
PAD: 12% 
 14.4% 
(bil: 3.1%)  
-Age per 10 year, OR:1.7 
-Female gender. OR:1.9 
-A.A.A or lower limb PAD,  
OR: 2.1 
-Carotid, OR: 3.0 
Zhang, 
2006 
CAD: 1,200 62+10 51% NA 
 9.7% 
(bil: 1.7%) 
Age, hypertension, renal 
insufficiency, CAD  
Ozkan, 
2009 
PAD: 629 62+11 43% 
Aortoiliac, crural, 
femoropopliteal: 83% 
9.6%§ 
Age, hypertension and 
aortoiliac stenosis 
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ANG 
(Patient: n) 
Age 
(year) 
CAD  
(%) 
PAD 
(%) 
ARVD   
(%) 
Predictors 
Kuroda, 
2000 
Stroke: 346 69+11 33% 
-Carotid: 29.2% 
-A.A.A: 13.3% 
10.4%* 
-Renal insufficiency, OR: 6.6 
-Hypertension:, OR: 4.1 
-Carotid >50%, OR: 4.8 
-Female gender, OR: 3.4 
Fujii, 
2006 
Stroke: 346 71+11 39% NA 
26.1%* 
(bil: 19%) 
Hypertension, renal 
insufficiency, PAD 
Table 1. Associations between systemic atherosclerosis and ARVD: n: number; ANG: renal 
angiography; CAD: coronary artery stenosis>50%; ARVD: renal artery stenosis>50%; PAD: 
peripheral artery stenosis>50%; NA: not available; A.A.A: abdominal aortic aneurysm;; 
carotid: carotid artery stenosis>50%; HR: hazard ratio; OR: odds ratio; VD: number of 
diseased coronary artery; § renal artery stenosis>60%; * renal artery stenosis>75%. 
2.1.1 The nature course of ARVD 
According to the shear stress rule, ostial and proximal lesions are mostly encountered and 
20%-50% of cases are bilateral sites in ARVD (Safian & Textor, 2001). A significant 
progression of ARVD was observed in 11.1% of 14,152 subjects with high cardiovascular 
risks within a 2.6-year period in an angiographic study (Crowley et al, 1995) and in 35%-51% 
from 3 to 5 years in a doplex unltrasonography study (Caps et al, 1998). From these reports, 
the predictors to disease progression include old age, female gender, hypertension, diabetes 
and the presence of significant coronary artery disease or peripheral vascular disease in 
which the odds ratios range from 1.2 to 2.1. On the other hand, patients with ARVD are 
associated with approximately 2-times risk of the occurrence of adverse coronary events and 
mortality as compared to those without ARVD in a long-term follow-up (Conlon et al, 2001; 
Edwards et al, 2005).   
2.2 How to select patients at risk for prompt screening 
As prescribed previously, patients at higher risk for atherosclerosis should receive an 
advanced step for screening the presence of ARVD (table 2)  
Among these clinical features, the only statistically significant predictor to ARVD is the 
presence of abdominal bruit. The prevalence ranges from 6.5% to 31% in the healthy 
population (Watson & William, 1973), and 28% in hypertensive patients (Julius and Steward, 
1967). However, in patients with angiographically proven ARVD, the prevalence increases 
up to 80% (Turnbull, 1995). Besides, the sensitivity of a systolic-diastolic abdominal bruit in 
the diagnosis of RAS has been reported from 39% to 63% and the specificity of 90% to 99% 
((Turnbull, 1995). Thus, the presence of a systolic-diastolic bruit is highly suggestive of RAS 
and should be screened for, while the absence of a bruit does not exclude RAS (Rosener 
2001). 
2.2.1 Differential diagnosis 
Some clinical situations have to been addressed in the diffential diagnosis of ARVD (table 3). 
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Categories Criteria 
Physical findings -Abdominal or flank bruit 
Metabolic 
syndorme 
International Diabetes Federation:  
- Central obesity is defined as waist circumference with ethnicity specific 
values or if BMI is >30 kg/m², central obesity can be assumed and waist 
circumference does not need to be measured. 
And and any two of the following: 
-Triglycerides: > 150 mg/dl, or specific treatment for this lipid 
abnormality.  
- HDL cholesterol: < 40 mg/dl in males, < 50 mg/dl in females, or 
specific treatment for this lipid abnormality  
- BP: systolic BP > 130 mmHg or diastolic BP >85 mm Hg, or treatment 
of previously diagnosed hypertension.  
- FPG >100 mg/dl, or previously diagnosed type 2 diabetes. If 
FPG>100 mg/dl, OGTT glucose tolerance test is strongly 
recommanded but is not necessary to define presense of the syndrome 
Hypertension 
-Refractory hypertension (BP >160/95 mm Hg while receiving three or 
more antihypertensive agents) or associataed acute pulmonary edema 
-Accelerated hypertension (increase in BP>15% in 6 months) 
-Severe hypertension (DBP >115 mm Hg or Grade III or IV retinopathy)  
-Recent-onset (within the last 2 years) hypertension  
-Onset of hypertension after age 60 
Renal insufficiency 
-Elevated serum blood urea nitrogen > 20mg/dl or creatinine > 1.4 mg/dl 
-Cockcroft-Gault CrCl < 50 ml/min without clear etiology 
-Acute renal failure attributable to ACEI or ARB therapy 
Atheroscelrosis 
-Abdominal aortic atherosclerosis or lower extremity artery stenosis 
-Peripheral artery disease or carotid artery stenosis / ischemic stroke 
-Coronary artery disease > 2 vessel disease 
Table 2. Patients at risk for further ARVD screening. BP: blood pressure; DBP: diastolic BP; 
FPG: Fasting plasma glucose; OGTT: oral glucose tolerance test; CrCl: creatinine clearance; 
ACEI: ACE inhibitors; ARB: angiotensin II receptor blockers. 
 
Clinical situations Differential diagnosis 
Abdominal bruit 
Splenic arteriovenous fistula, hepatic cirrhosis, 
hepatoma, abdominal aortic aneurysm and coarctation, 
celiac artery compression syndrome, intestinal ischemia, 
and pancreatic carcinoma 
Rrogressive renal insufficiency 
or renovascular hypertension  
-Benign hypertensive nephrosclerosis 
-Atheroembolic renal disease 
Renal artery stenosis 
-Renal artery dissection 
-Fibromuscular dysplasia 
Table 3. Differential diagnosis of ARVD. 
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Most of these clinical situations could be differentiataed correctly by the image study such 
as computed tomography and renal angiography. They are not neccessry mutually exclusive  
and may be coexisted. For instance, benign hypertensive nephrosclerosis, a renal 
parenchymal disease can be present together with ARVD. Atheroembolic renal disease is 
associated with aortic manupulation or occurs spontaneously. The clinical features include 
abrupt decline of renal functions and evidence of atrial fibrillation with extrarenal embolism 
(Hazanov, 2004). Fibromuscular dysplasia (FMD) characterized by fibrous thickening in 
arterial wall usually involves 60%-75% of renal  and 25%-30% of carotid artery stenosis 
(Luscher et al, 1981; Gray et al 1996) and is respoisble for 25 % cases of renovascular 
hypertension (Pickering, 1989). In angiographic findings, FMD demostrates classic images of 
“ string-of-beads“ appearance, aneurysm, and focal or tubular stenosis. In conrast to ARVD, 
FMD occurs predominantly in young women of childbearing age and involves the middle 
and distal portion of main renal artery (Das et al, 2007). 
2.3 The screening and diagnostic modality  
With the progression of the technology, a variety of modalities emerge for screening and 
diagnosis of ARVD (table 4). In addition to renogram and nuclear scintigraphic captopril 
renogram, doplex ultrasonography has been used successfully to detect the presence of 
renal artery stenosis due to the non-invasive and contrast-free characteristics. However, it is 
usually limited by a wide operator-dependent variation, obesity of patient and time 
consuming. Magnetic resonance (MR) angiography increases the comparability between 
examinations (Fig. 1A). Both of the sensitivity and specificity are estimated within 90-95%. 
Till now, multi-detector computed tomography (MDCT) angiography (Fig. 1B) almost 
replaces the role of catheter angiography as the first diagnostic tool for ARVD because of its 
high utility and detection rate in evaluation of other abdominal problems.  
 
Categories Sensitivity/specificity PPV/NPV Limitations 
Renogram 75% /75% 50-75% /60% Almost for screening only 
Captopril renogram 83-90% / 80-93% 70-92% /60-100% Hypotension 
Doplex 
ultrasonography 
75-90% /62-90% 60% /95% 
Wide operator-dependent 
variation, time consuming 
MR angiography 88-95% /90-95% 60-75% /90-98% 
Gadolinium-induced 
renopathy 
MDCT angiography 94-100% / 93-100% 71-100% /95-100% Contrast-induced renopathy 
Catheter 
angiography 
100% 100% 
Contrast-induced renopathy, 
bleeding, arterial dissection, 
distal embolism 
Table 4. Diagnostic modalities for ARVD. PPV: positive predictive value; NPV: negative PV. 
2.4 Therapeutic indications 
As we know, ARVD is highly associated with systemic atherosclerosis and occurs after the 
occurrence of coronary artery disease and peripheral artery disease. Accordingly, an early 
medical intervention and risk factors reductions to prevent the development of ARVD in the  
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Fig. 1. A: MR angiography demonstrates a right ostial renal artery stenosis (an arrowhead); 
B: MDCT angiography demonstrates diffuse atherosclerosis of left renal artery (an 
arrowhead indicate the proximal lesion of left renal artery). 
presence of systemic atherosclerosis and many risk factors is important. On the other hand, 
a critically unilateral or bilateral stenosis of renal artery disease may need further 
mechanical manipulations such as renal angioplasty, stenting and bypass surgery. We will 
describe the two parts of therapy in detail in the following paragraphs. 
2.4.1 Medical treatment 
Life style modification and a control of established risk factors is the golden rule for most 
atherosclerotic vascular disease including diabetes, obesity, hypertension, low density 
lipoprotein cholesterol (LDL-C), inflammation and smoking. However, no reports prove the 
effect of medical control to reduce the occurrence of ARVD or prevent disease progression. 
It is reasonable that medical treatment should be started in middle-aged persons at risk to 
prevent ARVD. The choice of pharmacological agents and the goal aimed to achieve with or 
without vascular events will be listed in table 5. 
Among the antihypertensive agents, ACE inhibitors or angiotensin II receptor blockers 
(ARBs) are observed with the most effectiveness in control of the blood pressure for patients 
with ARVD (Dworkin & Jamerson, 2007). Surgical intervention should be considered if 
refractory hypertension persisits. However, adequate control of blood pressure by chronic 
administration of antihypertensive drugs can not be guarantteed the prevention of stenotic 
lesions progression and post-stenotic renal.atrophy. 
2.4.2 Interventional treatment  
Renal artery revascularization for bilateral or unilateral disease in a single viable kidney is 
indicated in the following situations (Greco & Breyer, 1997; Textor, 2004). 
1. Severe or refractory hypertension 
2. Recurrent episodes of acute pulmonary edema  
3. Unexplained progressive renal insufficiency  
4. Progressive renal function impairment with optimal blood pressure control. 
Beyond these criteria mentioned above, the procedure of revascularization should be 
performed after weighing the benefits against the hazards. Therefore revascularization  
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Risk factors Medications (non) CVD / Goal Precautious 
Diabetes 
mellitus 
Insulin, secretagogues, 
sensitizers, 
α-glucosidase 
inhibitors, 
peptide analogs 
Non-CVD/ HbA1c< 6.5 % 
CVD/ LDL-C < 7.0 % 
Adverse cadiovascualr 
effects and metabolic 
abnormalities of anti-
diabetic agents  
Hypertension 
ACEI/ ARB, 
BB, CB, 
diuretics 
Non-CVD/ BP< 120/85 
mg/L 
CVD/ BP< 140/90mg/dl 
-A J-curve relationship 
between hypertension and 
cardiovascular mortality 
-ACEI/ARB should be used 
carefully in bilateral ARVD 
LDL-C 
Statin, fibrates, resins, 
niacin, ezetimibe,  
Non-CVD/ LDL-C< 100 
mg/L 
CVD/ LDL-C < 70mg/dl 
Multi-drug interaction and 
dose effect related 
rhabdomyolysis 
Inflammation 
-Antiplatelet agents 
-Statin 
-Investagated drugs 
Non-CVD/ hs-CRP< 2mg/L
CVD/ not established 
According to the JUPITER 
trial only (Ridker et al, 2008) 
Table 5. Modifiable risk factors for ARVD. CVD: cardiovascular disease including 
myocardial infarction and ischemic stroke; ACEI: ACE inhibitors; ARB: angiotensin II 
receptor blockers; BP: blood pressure; BB: beta-blocker; CB: calcium receptor blocker; 
JUPITER: Justification for the Use of Statins in Primary Prevention: An Intervention Trial 
Evaluating Rosuvastatin trial; CRP: C-reactive protein. 
should be aimed for patients with a reversible status of chronic renal insufficiency and 
resistant hypertension instead of reduing their mortality. A review literature has 
demonstrated that half of patients with ARVD have no change in renal function, while one 
fourth improve and one fifth deterioate their renal function after renal stenting (Fig.1A & B) 
(Leertouwer et al, 2000). 
 
Fig. 2. An atherosclerotic ostial lesion at right renal artery. Panel A: catheter renal 
angiography (An arrowhead indicates a lesion from ostial to proximal right renal artery; 
Panel B: post-percutaneous transluminal angioplasty with stenting (An arrowhead indicates 
stenting site of right renal artery).  
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Accordingly, only 20-25% of patients may be eligible for elective renal revascularization. 
There have some image, histology and clinical evidence to select patients with ARVD 
having benefits to undergo renal artery revascularization which is described as follow 
(Novick et al, 1987; Muray et al, 2002). 
1. Visualization of the collecting system either on an intravenous pyelogram or during the 
pyelogram phase after renal arteriography 
2. Kidney length ≥9 cm. 
3. The presence of intact glomeruli on frozen section biopsy at the time of surgery.  
4. Rapid decline of renal functions after ACEI/ARB administrations. 
There are three methods for renal artery revascularization (table 6). 
 
Revascularization  Indications Comments 
PTA without stenting 
(Connolly et al, 1994) 
Non-ostial lesions 
-65-70% success rate for lesions 
-35-50% improvement of renal 
functions 
PTA with stenting 
(ASTRAL investigators, 
2009; Stone et al, 2011; 
White, 2010; Davies et al, 
2009) 
Ostial and non-ostial lesions 
-Significantly lower restenosis 
rate than PTA alone 
-98.8% success rate for lesions 
-10.6-19% TVR rate within 5-10 
years period 
-Inconclusive results of the 
improvement of renal functions 
-Complication rate: 9% in 24 
hours; 20% in 1 month; 
mortality rate <1%   
Bypass surgery 
(ACC/AHA 2005 
guidelines; Hansen et al, 
1992) 
-Multiple small renal arteries 
-Early primary branching of 
the main renal artery 
-Aortic reconstruction near 
the renal arteries  
-85-90% success rate for lesions 
-55-65% improvement of 
lesions of renal functions 
-In-hospital mortality rate: 3-
10% 
Table 6. Comparison of three types of revascularization intervention. PTA: percutaneous 
transluminal angioplasty; TVR: target vessel revascularization; ASTRAL: Angioplasty and 
Stenting for Renal Artery Lesions; ACC/AHA: American College of Cardiology 
Foundation/American Heart Association. 
3. Conclusion  
ARVD reflecting a status of systemic atherosclerosis is associated with chronic renal disease. 
Life style modification and risk factors reduction are important for the primary prevention 
of ongoing renal dysfunction and secondary prevention of subsequent cardiovascular 
events. Some clinical features of patients at risk for ARVD should be highlighted and both 
medical treatment and mechanical procedures should be taken as early as possible if 
uncontrolled hypertension leading to end-organ damage or progressive renal insufficiency 
develops.   
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